Article Versions Notes

Vlayen S, Dierckx T, Caruso M, Sieben S, De Keersmaecker K, Daelemans D, Delforge M. Genome-Wide CRISPR-Cas9 Knockout Screening Identifies NUDCD2 Depletion as Sensitizer for Bortezomib, Carfilzomib and Ixazomib in Multiple Myeloma. Hemato. 2025; 6(3):21. https://doi.org/10.3390/hemato6030021

Vlayen, Sophie, Tim Dierckx, Marino Caruso, Swell Sieben, Kim De Keersmaecker, Dirk Daelemans, and Michel Delforge. 2025. "Genome-Wide CRISPR-Cas9 Knockout Screening Identifies NUDCD2 Depletion as Sensitizer for Bortezomib, Carfilzomib and Ixazomib in Multiple Myeloma" Hemato 6, no. 3: 21. https://doi.org/10.3390/hemato6030021

Vlayen, S., Dierckx, T., Caruso, M., Sieben, S., De Keersmaecker, K., Daelemans, D., & Delforge, M. (2025). Genome-Wide CRISPR-Cas9 Knockout Screening Identifies NUDCD2 Depletion as Sensitizer for Bortezomib, Carfilzomib and Ixazomib in Multiple Myeloma. Hemato, 6(3), 21. https://doi.org/10.3390/hemato6030021